GLTO Sep 2024 2.500 call
| Previous Close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 0.0400 - 0.0400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 298 |
GlobeNewswireGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto’s GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinomaBOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for ca
ZacksGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksWhat Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
